Cardiogen

Also known as: Heart Peptide Bioregulator, Cardiac Bioregulator

A bioregulator peptide for cardiovascular health and cardiac tissue support.

Overview

Cardiogen is a synthetic tetrapeptide from the Khavinson bioregulator family designed to support heart function. It has been studied in Russia for various cardiovascular conditions and shows promise for cardiac aging and rehabilitation.

Mechanism of Action

Gene regulatory effects on cardiomyocytes. Proposed to normalize protein synthesis in cardiac tissue. May support mitochondrial function and reduce oxidative stress in heart cells.

Pharmacokinetics

Small peptide allows oral/sublingual administration. Tissue-specific effects on cardiac tissue.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Maintenance

Dose

10-20 mg

Frequency

1-2x daily

Duration

10-30 days

2-3 courses per year

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Mitochondrial support

Synergy: Enhanced cardiac mitochondrial function

Research Areas

Cardiovascular HealthHeart FailureCardiac AgingPost-MI RecoveryArrhythmiaCardiomyopathy

Key Research Findings

  • 1Improved cardiac function markers in elderly patients
  • 2Gene expression modulation in cardiac tissue
  • 3Potential cardioprotective effects
  • 4Part of geroprotective protocols in Russia

Side Effects & Contraindications

Reported Side Effects

  • Generally well-tolerated

Contraindications

  • Acute MI (seek emergency care)

Safety Considerations

Generally well-tolerated. Should complement, not replace, standard cardiac care.

Storage Requirements

Store at room temperature

Scientific References

Quick Reference

Sequence
Ala-Glu-Asp-Arg
Molecular Weight
~489 g/mol
Half-Life
Short
Bioavailability
Oral/sublingual
Research Stage
clinical phase 2
Administration
Oral or sublingual